Effects of exemestane and tamoxifen in a postmenopausal breast cancer model

Danijela Jelovac, Luciana Macedo, Venkatesh Handratta, Brian J. Long, Olga G. Goloubeva, James N. Ingle, Angela M H Brodie

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Purpose: To optimize treatment strategies for postmenopausal breast cancer patients, we investigated the efficacy of the steroidal aromatase inhibitor exemestane alone or in combination with the antiestrogen tamoxifen in a xenograft model of postmenopausal breast cancer. We also determined the effects of these agents in sequential second-line therapy and the effect of the nonsteroidal aromatase inhibitor letrozole on tumors that progressed on the above treatments. Experimental: Aromatase-transfected human estrogen receptor-positive breast cancer cells (MCF-7Ca) were grown as tumors in ovariectomized athymic mice. Animals received subcutaneous injection with vehicle, tamoxifen, exemestane, tamoxifen plus exemestane, and letrozole. Tumor volumes were measured weekly. Results: All treatments were effective initially in suppressing umor growth as first-line therapy compared with vehicle treatment. Exemestane suppressed tumor growth to a greater extent than tamoxifen. However, the combination of tamoxifen plus exemestane was more effective than either drug alone. After tumor volumes doubled on initial treatment, the mice were crossed over to receive exemestane or tamoxifen. Tumor growth slowed briefly in mice treated with tamoxifen and crossed over to exemestane, but tumor growth continued unabated in those changed from exemestane to tamoxifen. However, letrozole was effective in both groups as third-line therapy for a limited period. Letrozole as initial single agent was the best overall treatment in terms of the degree of tumor suppression and the length of effectiveness of treatment. Conclusion: Exemestane was more effective in controlling tumor growth than tamoxifen. In addition, the combination of exemestane plus tamoxifen was clearly more effective than sequential use of these agents in the tumor model. However, the nonsteroidal aromatase inhibitor letrozole as first-line therapy was overall the most effective treatment in controlling tumor growth.

Original languageEnglish (US)
Pages (from-to)7375-7381
Number of pages7
JournalClinical Cancer Research
Volume10
Issue number21
DOIs
StatePublished - Nov 1 2004
Externally publishedYes

Fingerprint

exemestane
letrozole
Tamoxifen
Breast Neoplasms
Neoplasms
Aromatase Inhibitors
Growth
Therapeutics
Tumor Burden

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Jelovac, D., Macedo, L., Handratta, V., Long, B. J., Goloubeva, O. G., Ingle, J. N., & Brodie, A. M. H. (2004). Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. Clinical Cancer Research, 10(21), 7375-7381. https://doi.org/10.1158/1078-0432.CCR-04-0565

Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. / Jelovac, Danijela; Macedo, Luciana; Handratta, Venkatesh; Long, Brian J.; Goloubeva, Olga G.; Ingle, James N.; Brodie, Angela M H.

In: Clinical Cancer Research, Vol. 10, No. 21, 01.11.2004, p. 7375-7381.

Research output: Contribution to journalArticle

Jelovac, D, Macedo, L, Handratta, V, Long, BJ, Goloubeva, OG, Ingle, JN & Brodie, AMH 2004, 'Effects of exemestane and tamoxifen in a postmenopausal breast cancer model', Clinical Cancer Research, vol. 10, no. 21, pp. 7375-7381. https://doi.org/10.1158/1078-0432.CCR-04-0565
Jelovac D, Macedo L, Handratta V, Long BJ, Goloubeva OG, Ingle JN et al. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. Clinical Cancer Research. 2004 Nov 1;10(21):7375-7381. https://doi.org/10.1158/1078-0432.CCR-04-0565
Jelovac, Danijela ; Macedo, Luciana ; Handratta, Venkatesh ; Long, Brian J. ; Goloubeva, Olga G. ; Ingle, James N. ; Brodie, Angela M H. / Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 21. pp. 7375-7381.
@article{83ee6f1ea0c64a9d91d1e823b1812599,
title = "Effects of exemestane and tamoxifen in a postmenopausal breast cancer model",
abstract = "Purpose: To optimize treatment strategies for postmenopausal breast cancer patients, we investigated the efficacy of the steroidal aromatase inhibitor exemestane alone or in combination with the antiestrogen tamoxifen in a xenograft model of postmenopausal breast cancer. We also determined the effects of these agents in sequential second-line therapy and the effect of the nonsteroidal aromatase inhibitor letrozole on tumors that progressed on the above treatments. Experimental: Aromatase-transfected human estrogen receptor-positive breast cancer cells (MCF-7Ca) were grown as tumors in ovariectomized athymic mice. Animals received subcutaneous injection with vehicle, tamoxifen, exemestane, tamoxifen plus exemestane, and letrozole. Tumor volumes were measured weekly. Results: All treatments were effective initially in suppressing umor growth as first-line therapy compared with vehicle treatment. Exemestane suppressed tumor growth to a greater extent than tamoxifen. However, the combination of tamoxifen plus exemestane was more effective than either drug alone. After tumor volumes doubled on initial treatment, the mice were crossed over to receive exemestane or tamoxifen. Tumor growth slowed briefly in mice treated with tamoxifen and crossed over to exemestane, but tumor growth continued unabated in those changed from exemestane to tamoxifen. However, letrozole was effective in both groups as third-line therapy for a limited period. Letrozole as initial single agent was the best overall treatment in terms of the degree of tumor suppression and the length of effectiveness of treatment. Conclusion: Exemestane was more effective in controlling tumor growth than tamoxifen. In addition, the combination of exemestane plus tamoxifen was clearly more effective than sequential use of these agents in the tumor model. However, the nonsteroidal aromatase inhibitor letrozole as first-line therapy was overall the most effective treatment in controlling tumor growth.",
author = "Danijela Jelovac and Luciana Macedo and Venkatesh Handratta and Long, {Brian J.} and Goloubeva, {Olga G.} and Ingle, {James N.} and Brodie, {Angela M H}",
year = "2004",
month = "11",
day = "1",
doi = "10.1158/1078-0432.CCR-04-0565",
language = "English (US)",
volume = "10",
pages = "7375--7381",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Effects of exemestane and tamoxifen in a postmenopausal breast cancer model

AU - Jelovac, Danijela

AU - Macedo, Luciana

AU - Handratta, Venkatesh

AU - Long, Brian J.

AU - Goloubeva, Olga G.

AU - Ingle, James N.

AU - Brodie, Angela M H

PY - 2004/11/1

Y1 - 2004/11/1

N2 - Purpose: To optimize treatment strategies for postmenopausal breast cancer patients, we investigated the efficacy of the steroidal aromatase inhibitor exemestane alone or in combination with the antiestrogen tamoxifen in a xenograft model of postmenopausal breast cancer. We also determined the effects of these agents in sequential second-line therapy and the effect of the nonsteroidal aromatase inhibitor letrozole on tumors that progressed on the above treatments. Experimental: Aromatase-transfected human estrogen receptor-positive breast cancer cells (MCF-7Ca) were grown as tumors in ovariectomized athymic mice. Animals received subcutaneous injection with vehicle, tamoxifen, exemestane, tamoxifen plus exemestane, and letrozole. Tumor volumes were measured weekly. Results: All treatments were effective initially in suppressing umor growth as first-line therapy compared with vehicle treatment. Exemestane suppressed tumor growth to a greater extent than tamoxifen. However, the combination of tamoxifen plus exemestane was more effective than either drug alone. After tumor volumes doubled on initial treatment, the mice were crossed over to receive exemestane or tamoxifen. Tumor growth slowed briefly in mice treated with tamoxifen and crossed over to exemestane, but tumor growth continued unabated in those changed from exemestane to tamoxifen. However, letrozole was effective in both groups as third-line therapy for a limited period. Letrozole as initial single agent was the best overall treatment in terms of the degree of tumor suppression and the length of effectiveness of treatment. Conclusion: Exemestane was more effective in controlling tumor growth than tamoxifen. In addition, the combination of exemestane plus tamoxifen was clearly more effective than sequential use of these agents in the tumor model. However, the nonsteroidal aromatase inhibitor letrozole as first-line therapy was overall the most effective treatment in controlling tumor growth.

AB - Purpose: To optimize treatment strategies for postmenopausal breast cancer patients, we investigated the efficacy of the steroidal aromatase inhibitor exemestane alone or in combination with the antiestrogen tamoxifen in a xenograft model of postmenopausal breast cancer. We also determined the effects of these agents in sequential second-line therapy and the effect of the nonsteroidal aromatase inhibitor letrozole on tumors that progressed on the above treatments. Experimental: Aromatase-transfected human estrogen receptor-positive breast cancer cells (MCF-7Ca) were grown as tumors in ovariectomized athymic mice. Animals received subcutaneous injection with vehicle, tamoxifen, exemestane, tamoxifen plus exemestane, and letrozole. Tumor volumes were measured weekly. Results: All treatments were effective initially in suppressing umor growth as first-line therapy compared with vehicle treatment. Exemestane suppressed tumor growth to a greater extent than tamoxifen. However, the combination of tamoxifen plus exemestane was more effective than either drug alone. After tumor volumes doubled on initial treatment, the mice were crossed over to receive exemestane or tamoxifen. Tumor growth slowed briefly in mice treated with tamoxifen and crossed over to exemestane, but tumor growth continued unabated in those changed from exemestane to tamoxifen. However, letrozole was effective in both groups as third-line therapy for a limited period. Letrozole as initial single agent was the best overall treatment in terms of the degree of tumor suppression and the length of effectiveness of treatment. Conclusion: Exemestane was more effective in controlling tumor growth than tamoxifen. In addition, the combination of exemestane plus tamoxifen was clearly more effective than sequential use of these agents in the tumor model. However, the nonsteroidal aromatase inhibitor letrozole as first-line therapy was overall the most effective treatment in controlling tumor growth.

UR - http://www.scopus.com/inward/record.url?scp=8444235918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8444235918&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-0565

DO - 10.1158/1078-0432.CCR-04-0565

M3 - Article

VL - 10

SP - 7375

EP - 7381

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 21

ER -